AVL 3288

Drug Profile

AVL 3288

Alternative Names: Anvylic-3288; AVL-3288; UCI-4083

Latest Information Update: 11 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Anvyl Pharmaceuticals
  • Developer Anvyl
  • Class Neuroprotectants; Nootropics; Small molecules
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cognition disorders

Highest Development Phases

  • Phase I Cognition disorders

Most Recent Events

  • 16 Sep 2017 University of Maryland plans a phase I trial for Cognition disorders (NCT03281694)
  • 15 Dec 2016 Biomarkers information updated
  • 01 Nov 2016 New York State Psychiatric Institute and National Institute of Mental Health initiate a phase I trial for Cognition disorders associated with schizophrenia in USA (PO) (NCT02978599)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top